Catalog No.
DHE26301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
B-cell-specific glycoprotein B29, CD79B, B-cell antigen receptor complex-associated protein beta chain, Ig-beta, B29, Immunoglobulin-associated B29 protein, IGB, CD79b
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P40259
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ACD79B-VCMMAE, DCDS4501A, FCU2711, RO5541077-000, polatuzumab vedotin-piiq, CAS: 1313206-42-6
Clone ID
Polatuzumab
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 31693429
Polatuzumab Vedotin: First Global Approval, PMID: 31352604
Polatuzumab Vedotin: a New Target for B Cell Malignancies, PMID: 32172360
Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma, PMID: 32700972
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma, PMID: 32700586
Polatuzumab vedotin for B-cell lymphoma, PMID: 33363310
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data, PMID: 32606733
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS), PMID: 30935953
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study, PMID: 31101489
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab, PMID: 32309823
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study, PMID: 25925619
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis, PMID: 33431309
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience, PMID: 32981410
Antibodies to watch in 2020, PMID: 31847708
Polatuzumab Vedotin Approved for DLBCL, PMID: 31242994
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma, PMID: 32954807
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma, PMID: 32705923
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, PMID: 32500753
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study, PMID: 33029633
Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin, PMID: 32985934
Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients, PMID: 32974076
Correction to: Polatuzumab Vedotin: First Global Approval, PMID: 31617142
Excellent Interim Treatment Response with Polatuzumab Vedotin, PMID: 32608220
Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 31770050
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma, PMID: 32835553
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 33202794
Antibodies to watch in 2019, PMID: 30516432
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma, PMID: 32222808
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma, PMID: 33028076
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials, PMID: 33205435
Recent advances of antibody drug conjugates for clinical applications, PMID: 33088681
Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin, PMID: 31270798
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients, PMID: 33230948
Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies, PMID: 32521386
Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma, PMID: 33047089
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma, PMID: 31749251
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma, PMID: 31548805
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma, PMID: 32715803
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes, PMID: 25708834
ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma, PMID: 32421455
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma, PMID: 33258982
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, PMID: 32770353
A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma, PMID: 33001384
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas, PMID: 34196677
Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY ®) Antibody-Drug Conjugate in Sprague Dawley Rats, PMID: 33806916
Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens, PMID: 28544534
Pharmaceutical Approval Update, PMID: 31485143
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma, PMID: 27416486
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), PMID: 25768997
Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy, PMID: 33719894
For research use only. Not for human or drug use.
